Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RORC | P51449 | 6/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309505 | 1.00 | LMNA (0.66) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2610312 | 0.90 | KDM4E (0.71) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL5100563 | 0.90 | KDM4E (0.61) | LMNAKDM4ERORCNR4A2CYP1A2 | |
| SCHEMBL30309433 | 0.90 | KDM4E (0.61) | LMNAKDM4ERORCNR4A2CYP1A2 | |
| SCHEMBL16207451 | 0.87 | LMNA (0.53) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17883637 | 0.87 | LMNA (0.53) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30309442 | 0.87 | LMNA (0.53) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL4079943 | 0.86 | LMNA (0.55) | LMNAKDM4ERORCNR4A2CYP1A2 | |
| SCHEMBL10516924 | 0.86 | LMNA (0.60) | LMNAKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30309390 | 0.86 | LMNA (0.55) | LMNAKDM4ERORCNR4A2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | claimed |
| CN-115784987-A | Compound related to pneumonia, preparation method and application thereof, and pharmaceutical composition | 国科温州研究院(温州生物材料与工程研究所) | 2023-03-14 | — | — | CN | disclosed |
| CN-108948014-A | 1- aryl -4- Oxy-1, the preparation and application of the pyrido heterocycle compound of 4- dihydroquinoline structure | 江西科技师范大学 | 2018-12-07 | — | — | CN | disclosed |
| EP-2799437-B1 | QUINOLINE AND CINNOLINE DERIVATIVES AND USE THEREOF | UNIV SHENYANG PHARMACEUTICAL (CN) | 2016-09-14 | — | — | EP | disclosed |
| US-9382232-B2 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2016-07-05 | — | — | US | disclosed |
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2014-12-11 | — | — | US | disclosed |
| EP-2799437-A1 | QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF | Shenyang Pharmaceutical University (CN) | 2014-11-05 | — | — | EP | disclosed |
| EP-0360258-A2 | Amino acid quinoline and naphthyridine derivatives | ABBOTT LABORATORIES (US) | 1990-03-28 | — | — | EP | disclosed |
| EP-0251308-A1 | 4-Quinolone-3-carboxylic-acid derivatives, process for their synthesis and pharmaceutical preparations containing them | Chemie Linz Gesellschaft m.b.H. (AT) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364431-A1 | Quinoline and cinnoline derivatives and their applications | MET, CHEK1, KIT | LMNA 1240/4885KDM4E 2948/4885MEN1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.